Zuellig Pharma Acquires Zam-Buk and Vapex Brands from Bayer
This acquisition allows Zuellig Pharma to enhance its consumer healthcare offerings in the APAC region, tapping into established brands with significant market presence.
Acquisition of Zam-Buk and Vapex brands from Bayer to expand consumer healthcare portfolio.
Zuellig Pharma has strengthened its consumer healthcare portfolio by acquiring the Zam-Buk® and Vapex® brands from Bayer. This strategic acquisition aims to expand Zuellig Pharma's presence and offerings within the consumer healthcare market across Asia, leveraging the established brand recognition and market reach of the acquired products. The deal underscores Zuellig Pharma's commitment to growing its consumer health segment.
This acquisition allows Zuellig Pharma to enhance its consumer healthcare offerings in the APAC region, tapping into established brands with significant market presence. It signifies a strategic move to bolster its position in a growing market segment, potentially leading to increased accessibility of these products for consumers across various Asian countries and strengthening Zuellig Pharma's overall market share in consumer health.
The acquisition directly impacts the APAC region by expanding Zuellig Pharma's consumer healthcare portfolio with well-known brands, aiming to improve product accessibility and market penetration across multiple Asian markets.
Where this signal fits in the broader landscape.
https://www.zuelligpharma.com/news-insights/Zuellig-Pharma-Strengthens-Consumer-Healthcare-Portfolio-with-the-Acquisition-of-Zam-Buk-and-Vapex-Brands-from-Bayer
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
Sign In